Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RBP4 | P02753 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | DRD3 | P35462 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Retinol SCHEMBL15592 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL1580302 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL3113 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL19660979 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL3112 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL1433566 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Zuretinol SCHEMBL254333 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL15593 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL8360234 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA | |
| Retinol SCHEMBL14619410 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4APPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700128-A1 | MICROBIAL OIL COMPOSITION COMPRISING RETINOIDS AND FATTY ACIDS | CJ Cheiljedang Corporation (KR) | 2026-02-25 | — | — | EP | claimed |
| EP-4594492-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-12252724-B2 | Biosynthesis of retinoids | DSM IP ASSETS B.V. (NL) | 2025-03-18 | — | — | US | claimed |
| WO-2024225818-A1 | MICROBIAL OIL COMPOSITION COMPRISING RETINOIDS AND FATTY ACIDS | 씨제이제일제당 (주) | 2024-10-31 | — | — | WO | claimed |
| EP-4373937-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| WO-2024085763-A1 | AN IN VITRO METHOD FOR PRODUCING A 3D-STRUCTURE OF CELLS | UNIVERSITEIT MAASTRICHT (NL) | 2024-04-25 | — | — | WO | claimed |
| WO-2024073732-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024042550-A1 | OPHTHALMIC COMBINATION COMPOSITION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | claimed |
| US-20230227862-A1 | BIOSYNTHESIS OF RETINOIDS | DSM IP ASSETS B.V. (NL) | 2023-07-20 | — | — | US | claimed |
| EP-0725623-A1 | COSMETIC COMPOSITION COMPRISING A HYDROCALCHONE AND OPTIONALLY RETINOL OR A DERIVATIVE THEREOF | UNILEVER PLC (GB) | 1996-08-14 | — | — | EP | claimed |
| US-5545399-A | MIXTURE OF HYDROCHALCONE DERIVATIVE AND RETINOL OR DERIVATIVE THEREOF | CHESEBROUGH-POND'S USA CO. (US) | 1996-08-13 | — | — | US | claimed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | claimed |
| EP-0666735-A1 | RETINOL CONTAINING COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1995-08-16 | — | — | EP | claimed |
| EP-0662818-A1 | COSMETIC COMPOSITION CONTAINING RETINOL | UNILEVER PLC (GB) | 1995-07-19 | — | — | EP | claimed |
| WO-1995011662-A1 | COSMETIC COMPOSITION COMPRISING A HYDROCALCHONE AND OPTIONALLY RETINOL OR A DERIVATIVE THEREOF | UNILEVER PLC (GB) | 1995-05-04 | — | — | WO | claimed |
| WO-1994009756-A1 | RETINOL CONTAINING COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1994-05-11 | — | — | WO | claimed |
| WO-1994007462-A1 | COSMETIC COMPOSITION CONTAINING RETINOL | UNILEVER PLC (GB) | 1994-04-14 | — | — | WO | claimed |
| EP-0397774-A1 | FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-11-22 | — | — | EP | claimed |
| WO-1989006977-A1 | FORMULATION AND USE OF RETINOIDS IN TREATMENT OF CANCER AND OTHER DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | ALDH1A1 1700/4885MAPT 293/4885CYP3A4 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.